Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,664 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sham (Control) Clear all

Conditions: Overactive Bladder (OAB)
Interventions: NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham; Combination Product
Lead sponsor: Vensica Therapeutics Ltd.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Margate, Florida • Pompano Beach, Florida • Reno, Nevada

Conditions: Emphysema
Interventions: Exhale® Drug-Eluting Stent, Sham control; Device
Lead sponsor: Broncus Technologies; Industry
Eligibility: 35 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 26
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 21 more

Conditions: Breast Cancer
Interventions: Exercise + transcranial alternating current stimulation (Ex+tACS), Control; Behavioral
Lead sponsor: Florida Atlantic University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Dental Caries
Interventions: Ferumoxytol/Hydrogen peroxide, Hydrogen Peroxide, Water; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Indianapolis, Indiana • Philadelphia, Pennsylvania

Conditions: ADHD
Interventions: methylphenidate transdermal system, Placebo; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more

Conditions: Opioid-use Disorder
Interventions: Active repetitive transcranial magnetic stimulation (rTMS), Sham repetitive transcranial magnetic stimulation (rTMS); Device
Lead sponsor: Rutgers University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Chronic Low Back Pain
Interventions: Enso device; Device
Lead sponsor: Thimble Bioelectronics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Pancreatitis, Recurrent Pancreatitis
Interventions: Gut Directed VR, Sham Control VR; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Peripheral Neuropathy
Interventions: Active Provant Therapy System, Inactive (sham) Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Sham Intervention, Survey Administration, Transcranial Direct Current Stimulation; Procedure · Other · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Neurogenic Pain
Interventions: Transcranial magnetic stimulation, Sham; Device · Other
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Androgenetic Alopecia
Interventions: LH80 PRO, Sham Device; Device
Lead sponsor: Theradome, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • Newnan, Georgia • Portland, Oregon + 1 more

Conditions: Acute Migraine
Interventions: Nerivio Migra neurostimulation, Sham Nerivio Migra; Device
Lead sponsor: Theranica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Albany, New York • Hartford, New York + 1 more

Conditions: Pain, Trigeminal Neuralgia, Neuropathic Pain
Interventions: laboratory pain assessment, transcranial magnetic stimulation; Device · Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diabetic Neuropathy Peripheral
Interventions: Active Provant Therapy System, Inactive (sham) Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Mesa, Arizona • Northridge, California • Sacramento, California + 15 more

Conditions: COPD
Interventions: PEP Buddy, PEP Buddy Sham; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Cincinnati, Ohio • Cleveland, Ohio

Conditions: Subluxation
Interventions: Sham adjustment, Chiropractic adjustment; Procedure
Lead sponsor: Life University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions: MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation; Device · Other
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 25 Years to 64 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Transauricular vagus nerve stimulation (taVNS); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Post-operative Surgical Pain
Interventions: Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Systolic Heart Failure
Interventions: neuromodulation device, SHAM; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: Spinal Fusion, Hyperglycemia, Postoperative Pain Management, Postoperative Care, Spine Disease, Neurologic Deficits, Neurological Disorder, Inflammation, Spine Condition, Spinal (Fusion) Surgery, Cytokine Levels, Spine Fusion
Interventions: Auricular vagus nerve stimulation, Sham Auricular Vagus nerve Stimulation; Device
Lead sponsor: Alexander T. Yahanda; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Infant, Extremely Low Birth Weight, Feeding Behavior
Interventions: NTrainer, SHAM blind pacifier; Device
Lead sponsor: University of Nebraska Lincoln; Other
Eligibility: Up to 24 Months
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • San Jose, California • Boston, Massachusetts + 1 more

Search by objective public record fields.

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

EASE Trial: Exhale Airway Stents for Emphysema

Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors

Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder

The Enso Study for Chronic Low Back Pain

VR Pilot for Pancreatitis

Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy

Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

Noninvasive Neuromodulation Of The Subjective Value Network In Chronic Pain

Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO

Migraine Treatment With Nerivio Migra Neurostimulation Device

Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception

Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy

PEP Buddy in Pulmonary Rehabilitation

Simulated vs Genuine Manual Chiropractic Adjustments

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

Understanding the Effects of Transauricular Vagus Nerve Stimulation on Neural Networks and Autonomic Nervous System

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

Neuromodulation of Inflammation and Endothelial Function

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery

Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants